文献速递流行病学与生物统计临床试验与 GCP

三臂试验「金标准」设计中盲法样本量再估计

Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
PubMed 文献 · Stat Med · 2017-06-12

研究在「金标准」三臂设计(含阳性对照、安慰剂对照和试验治疗)的模拟中比较多种盲法样本量再估计方法。基于常用单样本方差估计的再估计导致试验把握度过高,基于Xing-Ganju方差估计的再估计导致把握度不足,作者提出一种膨胀因子使把握度适当且不偏倚效应估计。

要点

  • 基于单样本方差估计的盲法样本量再估计导致试验把握度过高。
  • 基于Xing-Ganju方差估计的再估计导致把握度不足,符合预期。
  • 作者提出的膨胀因子可使基于Xing-Ganju方差估计的再估计获得适当把握度。

核心结论

  • 基于常用单样本方差估计的盲法样本量再估计导致试验把握度过高。
  • 基于无偏方差估计(如Xing-Ganju方差估计)的再估计导致把握度不足,因再估计过程通常需要高估方差从而高估样本量才能最终达到目标把握度。
  • 作者提出一种用于Xing-Ganju方差估计的样本量再估计膨胀因子,模拟显示该法可获得适当把握度。
  • 作者证明基于Xing-Ganju方差估计的样本量再估计不使效应估计产生偏倚。

研究设计与样本

  • 研究在「金标准」设计(含阳性对照、安慰剂对照和试验治疗的三臂临床试验设计)中,针对正态分布结局,开展带内部预试验的盲法样本量再估计研究。
  • 采用模拟研究比较多种盲法样本量再估计方法,评估把握度和I类错误等操作特征。

主要发现

  • 基于常用单样本方差估计的样本量再估计导致试验把握度过高。
  • 基于Xing-Ganju方差估计的样本量再估计导致试验把握度不足,符合预期。
  • 作者提出的膨胀因子可使基于Xing-Ganju方差估计的再估计获得适当把握度。
  • 由于Xing-Ganju方差估计具有无偏性且分布不依赖组均值,该膨胀因子不依赖冗余参数,可在试验前计算。
  • 作者证明基于Xing-Ganju方差估计的样本量再估计不使效应估计产生偏倚。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this article, we study blinded sample size re-estimation in the 'gold standard' design with internal pilot study for normally distributed outcomes. The 'gold standard' design is a three-arm clinical trial design that includes an active and a placebo control in addition to an experimental treatment. We focus on the absolute margin approach to hypothesis testing in three-arm trials at which the non-inferiority of the experimental treatment and the assay sensitivity are assessed by pairwise comparisons. We compare several blinded sample size re-estimation procedures in a simulation study assessing operating characteristics including power and type I error. We find that sample size re-estimation based on the popular one-sample variance estimator results in overpowered trials. Moreover, sample size re-estimation based on unbiased variance estimators such as the Xing-Ganju variance estimator results in underpowered trials, as it is expected because an overestimation of the variance and thus the sample size is in general required for the re-estimation procedure to eventually meet the target power. To overcome this problem, we propose an inflation factor for the sample size re-estimation with the Xing-Ganju variance estimator and show that this approach results in adequately powered trials. Because of favorable features of the Xing-Ganju variance estimator such as unbiasedness and a distribution independent of the group means, the inflation factor does not depend on the nuisance parameter and, therefore, can be calculated prior to a trial. Moreover, we prove that the sample size re-estimation based on the Xing-Ganju variance estimator does not bias the effect estimate. Copyright © 2017 John Wiley & Sons, Ltd.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Mütze T, Friede T. Blinded sample size re-estimation in three-arm trials with 'gold standard' design. Stat Med. 2017. PMID: 28608469. doi:10.1002/sim.7356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。